Current perspectives on tertiary lymphoid structures and PD-1/PD-L1 signaling pathway in the immunotherapy of hepatocellular carcinoma
In the entire world, hepatocellular carcinoma (HCC) is one of the most prevalent cancers. The discovery that HCC is intimately linked to programmed cell death-1 and its ligand (PD-1/PD-L1) in recent years has opened up new possibilities for immunotherapy. However, there are no reliable biomarkers fo...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of New Medicine
2023-10-01
|
| Series: | Yixue xinzhi zazhi |
| Subjects: | |
| Online Access: | https://yxxz.whuznhmedj.com/futureApi/storage/attach/2310/ObvDqjvIUH3aNnde6f2OXTYE9hQVp1koUOzbPg9z.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | In the entire world, hepatocellular carcinoma (HCC) is one of the most prevalent cancers. The discovery that HCC is intimately linked to programmed cell death-1 and its ligand (PD-1/PD-L1) in recent years has opened up new possibilities for immunotherapy. However, there are no reliable biomarkers for anti-PD-1/PD-L1 immunotherapy. The latest research has found that tertiary lymphoid structures (TLS) have certain predictive value for the anti PD-1/PD-L1 immunotherapy effect of HCC.This paper analyzes the potential of TLS and PD-1/PD-L1 signaling pathway in hepatocellular carcinoma and covers the mechanism of TLS and PD-1/PD-L1 signaling route, their expression in hepatocellular carcinoma, and particular research developments in the clinic. |
|---|---|
| ISSN: | 1004-5511 |